nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

20.04.2023 | case report

Excellent response of a disseminated SMARCA4-deficient thoracic sarcomatoid tumor to immunochemotherapy—a case report

verfasst von: Clemens Petrasch, MD, Simon Udovica, MD, Frédéric Witte, MD, Bernadette Liegl-Atzwanger, MD, Wolfgang Pokieser, MD, Siroos Mirzaei, MD, Wolfgang Hilbe, MD, Andrea Kaufmann-Keck, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Summary

A 68-year-old man was diagnosed with a SMARCA4-deficient thoracic sarcomatoid tumor. Immunochemotherapy with carboplatin, paclitaxel, and pembrolizumab followed by maintenance therapy with pembrolizumab resulted in clinically meaningful remission.

Vorheriger Artikel Molecular pathology of colorectal cancer

Nächster Artikel Neoadjuvant and adjuvant therapy in early breast cancer. A short review on current clinical approaches

Concepcion CP, Ma S, LaFave LM, Bhutkar A, Liu M, DeAngelo LP, Kim JY, Del Priore I, Schoenfeld AJ, Miller M, Kartha VK, Westcott PMK, Sánchez-Rivera FJ, Meli K, Gupta M, Bronson RT, Riely GJ, Rekhtman N, Rudin CM, Kim CF, Regev A, Buenrostro JD, Jacks T. Smarca4 inactivation promotes lineage-specific transformation and early metastatic features in the lung. Cancer Discov. 2022;12(2):562–85. https://doi.org/10.1158/2159-8290.CD-21-0248.CrossRefPubMed

Rekhtman N, Montecalvo J, Chang JC, Alex D, Ptashkin RN, Ai N, Sauter JL, Kezlarian B, Jungbluth A, Desmeules P, Beras A, Bishop JA, Plodkowski AJ, Gounder MM, Schoenfeld AJ, Namakydoust A, Li BT, Rudin CM, Riely GJ, Jones DR, Ladanyi M, Travis WD. SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas. J Thorac Oncol. 2020;15(2):231–47. https://doi.org/10.1016/j.jtho.2019.10.023.CrossRefPubMed

Schoenfeld AJ, Bandlamudi C, Lavery JA, Montecalvo J, Namakydoust A, Rizvi H, Egger J, Concepcion CP, Paul S, Arcila ME, Daneshbod Y, Chang J, Sauter JL, Beras A, Ladanyi M, Jacks T, Rudin CM, Taylor BS, Donoghue MTA, Heller G, Hellmann MD, Rekhtman N, Riely GJ. The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer. Clin Cancer Res. 2020;26(21):5701–8. https://doi.org/10.1158/1078-0432.CCR-20-1825.CrossRefPubMedPubMedCentral

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM, KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–51. https://doi.org/10.1056/NEJMoa1810865.CrossRefPubMed

Takada K, Sugita S, Murase K, Kikuchi T, Oomori G, Ito R, Hayasaka N, Miyanishi K, Iyama S, Ikeda H, Kobune M, Emori M, Kato J, Hasegawa T. Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report. Thorac Cancer. 2019;10(12):2312–5. https://doi.org/10.1111/1759-7714.13215. Erratum in: Thorac Cancer. 2020 Dec;11(12):3645.CrossRefPubMedPubMedCentral

Henon C, Blay JY, Massard C, Mir O, Bahleda R, Dumont S, Postel-Vinay S, Adam J, Soria JC, Le Cesne A. Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor. Ann Oncol. 2019;30(8):1401–3. https://doi.org/10.1093/annonc/mdz160.CrossRefPubMed

Shinno Y, Yoshida A, Masuda K, Matsumoto Y, Okuma Y, Yoshida T, Goto Y, Horinouchi H, Yamamoto N, Yatabe Y, Ohe Y. Efficacy of immune checkpoint inhibitors in SMARCA4-deficient thoracic tumor. Clin Lung Cancer. 2022;23(5):386–92. https://doi.org/10.1016/j.cllc.2022.03.005.CrossRefPubMed

Kunimasa K, Nakamura H, Sakai K, Tamiya M, Kimura M, Inoue T, Nishino K, Kuhara H, Nakatsuka SI, Nishio K, Imamura F, Kumagai T. Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events. Lung Cancer. 2019;132:59–64. https://doi.org/10.1016/j.lungcan.2019.03.029.CrossRefPubMed

Titel: Excellent response of a disseminated SMARCA4-deficient thoracic sarcomatoid tumor to immunochemotherapy—a case report
verfasst von: Clemens Petrasch, MD
Simon Udovica, MD
Frédéric Witte, MD
Bernadette Liegl-Atzwanger, MD
Wolfgang Pokieser, MD
Siroos Mirzaei, MD
Wolfgang Hilbe, MD
Andrea Kaufmann-Keck, MD
Publikationsdatum: 20.04.2023
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 2/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-023-00880-7

Molecular pathology of colorectal cancer

Open Access
review

ESMO update: upper gastrointestinal cancer

Open Access
short review

Selection of phase II/III breast cancer study highlights at the 2022 ESMO annual meeting

Open Access
short review

Lessons learned in adjuvant colorectal cancer

Open Access
short review

Colorectal cancer special, part 2

editorial

Spectrum of renal involvement in MGRS patients: a 6-year study

original report

Springer Medizin Österreich

Excellent response of a disseminated SMARCA4-deficient thoracic sarcomatoid tumor to immunochemotherapy—a case report

Summary

Weitere Artikel der Ausgabe 2/2023

Molecular pathology of colorectal cancer

ESMO update: upper gastrointestinal cancer

Selection of phase II/III breast cancer study highlights at the 2022 ESMO annual meeting

Lessons learned in adjuvant colorectal cancer

Colorectal cancer special, part 2

Spectrum of renal involvement in MGRS patients: a 6-year study

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Molecular pathology of colorectal cancer

ESMO update: upper gastrointestinal cancer

Selection of phase II/III breast cancer study highlights at the 2022 ESMO annual meeting

Lessons learned in adjuvant colorectal cancer

Colorectal cancer special, part 2

Spectrum of renal involvement in MGRS patients: a 6-year study